FORM FOR ADVANCE VOTING

by postal voting in accordance with section 3 of the Act (2020:198) on temporary exceptions to facilitate the execution of general meetings in companies and other associations

Submitted to Swedish Orphan Biovitrum AB (publ) no later than on 7 May 2020.

The shareholder below is hereby exercising the voting right for all of the shareholder's shares in Swedish Orphan Biovitrum AB (publ) ("**Sobi**"), Reg. No. 556038-9321 at the annual general meeting on 13 May 2020. The voting right is exercised in accordance with the below marked voting options.

Name of the shareholder	Personal identity number/registration number
m. 1	T
Telephone number	E-mail
Di 11.	
Place and date	
Signature	
Clarification of signature	

Instructions to vote in advance:

- Complete the shareholder information above
- Select the preferred voting options below
- Print, sign and send the form in the original to Swedish Orphan Biovitrum AB (publ), "Annual General Meeting", SE-112 76 Stockholm, Sweden. A completed and signed form may also be submitted electronically and shall, in that case, be sent to advancevoting@sobi.com
- If the shareholder is a legal entity, a copy of a registration certificate or a corresponding document for the legal entity shall be enclosed together with the form. The same applies if the shareholder votes in advance by proxy
- Please note that notice to attend the meeting shall be submitted no later than on 7 May 2020 even
 if the shareholder chooses to vote in advance. Instructions for this is included in the notice
 convening the meeting
- Please note that a shareholder whose shares have been registered in the name of a bank or securities institute must re-register its shares in its own name to vote. Instructions for this is included in the notice convening the meeting
- If a shareholder does not intend to exercise its voting right by way of advance voting, the form for advance voting should not be submitted

A shareholder cannot give any other instructions than selecting one of the options specified at each point in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote (i.e. the advance voting in its entirety) is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented. One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by the company will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered.

The form, together with any enclosed authorisation documentation, shall be provided to Sobi no later than on 7 May 2020. An advance vote can be withdrawn up to and including 7 May 2020 by notifying this via e-mail to advancevoting@sobi.com. Thereafter, an advance vote can only be withdrawn if the shareholder is present, in person or by proxy, at the general meeting.

For complete proposals for the items on the agenda, kindly refer to the notice convening the meeting and the proposals on Sobi's web site.

For information on how your personal data is processed, see the integrity policy that is available at Euroclear's web site www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Annual general meeting in Swedish Orphan Biovitrum AB (publ) on $13 \ May \ 2020$

The options below comprise, if not otherwise stated in the form, the proposals submitted by the board of directors and the nomination committee which are included in the notice convening the annual general meeting.

2. Election of the chairman of the Meeting	
Yes □ No □	
4. Approval of the agenda	
Yes □ No □	
6. Determination of whether the Meeting has been duly convened	
Yes □ No □	
10. Resolution regarding adoption of the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet	
Yes □ No □	
11. Resolution regarding appropriation of the company's profit or loss in accordance with the adopted balance sheet	
Yes □ No □	
12. Resolution regarding discharge of the members of the Board of Directors and the managing director from liability	
12.1 David Allsop (member of the Board of Directors)	
Yes □ No □	
12.2 Håkan Björklund (chairman of the Board of Directors)	
Yes □ No □	
12.3 Annette Clancy (member of the Board of Directors)	
Yes □ No □	
12.4 Matthew Gantz (member of the Board of Directors)	
Yes □ No □	
12.5 Lennart Johansson (member of the Board of Directors)	
Yes □ No □	
12.6 Helena Saxon (member of the Board of Directors)	
Yes □ No □	
12.7 Hans GCP Schikan (member of the Board of Directors)	
Yes □ No □	
12.8 Elisabeth Svanberg (member of the Board of Directors)	
Yes □ No □	

12.9 Pia Axelson (member of the Board of Directors, employee representative)
Yes □ No □
12.10 Emily Chamberlain (member of the Board of Directors, employee representative)
Yes □ No □
12.11 Bo-Gunnar Rosenbrand (member of the Board of Directors, employee representative)
Yes □ No □
12.12 Kristin Strandberg (member of the Board of Directors, employee representative)
Yes □ No □
12.13 Guido Oelkers (CEO)
Yes □ No □
13. Determination of fees to be paid to the members of the Board of Directors and to the auditor
Yes □ No □
14. Determination of the number of directors and deputy directors and auditors and deputy auditors
Yes □ No □
15. Election of the chairman, the members of the Board of Directors and the auditor
15.a Håkan Björklund (member of the Board of Directors)
Yes □ No □
15.b Annette Clancy (member of the Board of Directors)
Yes □ No □
15.c Matthew Gantz (member of the Board of Directors)
Yes □ No □
15.d Lennart Johansson (member of the Board of Directors)
Yes □ No □
15.e Helena Saxon (member of the Board of Directors)
Yes □ No □
15.f Elisabeth Svanberg (member of the Board of Directors)
Yes □ No □
15.g Staffan Schüberg (member of the Board of Directors)
Yes □ No □
15.h Election of chairman of the Board of Directors – Håkan Björklund
Yes □ No □
15.i Election of auditor – Ernst & Young AB

Yes □ No □	
16. Resolution regarding guidelines for remuneration for the management	
Yes □ No □	
17. Resolution regarding amendments of the articles of association	
Yes □ No □	
18. Resolution regarding the implementation of a Management Programme and an All Employee Programme in accordance with A.I and A.II, respectively, and hedging arrangements in respect thereof in accordance with B or C	
18.A.I Implementation of a Management Programme	
Yes □ No □	
18.A.II Implementation of an All Employee Programme	
Yes □ No □	
18.B Directed issue of redeemable and convertible series C shares, authorisation for the Board of Directors to resolve to repurchase all issued redeemable and convertible series C shares and transfers of own common shares to the participants of the Programmes	
Yes □ No □	
18.C Equity swap agreement with a third party	
Yes □ No □	
19. Resolution regarding approval to authorise the issuance of new shares and/or convertible bonds and/or warrants	
Yes □ No □	
20. Resolution regarding transfer of own shares	
Yes □ No □	